Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study

Table 2

Univariate analysis of PFS among the 39 patients with advanced GC according to baseline characteristics.

Characteristic		Median PFS (months)	95% CI
Age (years)				0.439
≥61	21	3.9	2.89-4.91
<61	18	3.8	2.95-4.65
Gender				0.516
Male	26	3.5	2.67-4.33
Female	13	4.3	3.03-5.57
ECOG performance status score				0.015
0-1	25	4.6	3.37-5.83
2	14	2.8	1.89-3.71
Primary lesion				0.539
Gastric	30	4.3	3.24-5.36
Gastroesophageal junction	9	3.9	2.93-4.87
Lines of previous treatment				0.605
1	4	4.6	3.47-5.73
≥2	35	3.8	2.77-4.83
Previous targeted drugs therapy				0.637
Yes	7	3.9	2.97-4.83
No	32	3.7	2.85-4.55
History of gastrectomy				0.447
Yes	17	4.3	3.09-5.51
No	22	3.8	2.76-4.84
Number of metastatic sites
≤2	9	4.6	3.46-5.74	0.421
>2	30	3.8	2.98-4.62
Initial dosage of apatinib (mg)				0.417
500	22	4.3	3.13-5.47
250	17	3.8	2.88-4.72
PD-1 blockades
Camrelizumab	26	3.9	2.91-4.89	0.427
Sintilimab	8	3.5	2.41-4.59
Nivolumab	5	4.3	3.27-5.33

Abbreviations: GC: gastric cancer; ECOG: Eastern Cooperative Oncology Group; PD-1: programmed cell death protein 1.